O'Shaughnessy Asset Management’s Akebia Therapeutics AKBA Stock Holding History

O'Shaughnessy Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,379	Closed	-$10K	–	1285
2021 Q3	$10K	Sell	3,379 -11,314	-77%	-$32.3K	﹤0.01%	2157
2021 Q2	$56K	Buy	14,693 +14,637	+26,138%	+$49.3K	﹤0.01%	1534
2021 Q1	$0	Hold	56	–	–	﹤0.01%	2358
2020 Q4	$0	Hold	56	–	–	﹤0.01%	2060
2020 Q3	$0	Hold	56	–	–	﹤0.01%	1856
2020 Q2	$1K	Buy	+56	New	+$579	﹤0.01%	1555

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

O'Shaughnessy Asset Management's AKBA Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Akebia Therapeutics (AKBA) in Q4 2021, closing a stake of 3,379 shares — an estimated $10K sold.

O'Shaughnessy Asset Management first reported a position in AKBA in Q2 2020 and held it in 6 quarters. The position peaked at $56K in Q2 2021. 133 funds tracked by Wall St. Rank hold AKBA as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining Akebia Therapeutics position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 3,379 Akebia Therapeutics shares in Q4 2021, an estimated $10K.
O'Shaughnessy Asset Management first reported a position in Akebia Therapeutics in Q2 2020 and held it in 6 quarters.
O'Shaughnessy Asset Management's Akebia Therapeutics position peaked at $56K in Q2 2021.
133 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.